Clinical treatment and follow-up of the first critical cases of critical rift valley fever in China

doi:10.3877/cma.j.issn.1674-1358.2018.01.020

Abstract

Abstract:

Objective

To investigate the treatment of the first case of rift valley fever in China.

Methods

The clinical data, treatments, prognosis and follow up data of the first case of rift valley fever in China were analyzed, retrospectively.

Results

This case of rift valley fever critically ill patient was male, 45 years old, living in Angela for 2 years, there were no rift valley fever epidemic. The main clinical manifestations were fever, headache, abdominal muscle pain, progressive reduction in urine output. Laboratory tests suggested severe liver and kidney function damage. On the third day of admission, the rift valley fever virus was reported positive by the Chinese CDC, and other pathogens were negative and rift valley fever was confirmed. After continuous blood purification, liver protection, stable cell membrane and symptomatic support treatment, the urine output was gradually increased, liver and kidney function gradually recovered. Outpatient follow-up for six months, liver and kidney function of the case were normal, and the patient was discharged.

Conclusions

As a zoonotic disease, the risk of rift valley fever incoming to China is gradually increased. Acute renal failure and acute liver injury are the main manifestations of critical rift valley fever, it could be effectively controlled after treatment.

Key words: Imported transmitted diseases, Rift valley fever, Critically ill, Acute renal failure, Acute liver injury

Haofeng Xiong, Chuansheng Li, Jianbo Tan, Yufeng Liu, Yao Sun, Lin Pu, Pan Xiang, Min Zhang, Jingyuan Liu. Clinical treatment and follow-up of the first critical cases of critical rift valley fever in China[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(01): 98-101.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2018.01.020

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2018/V12/I01/98

Figures/Tables 1

References 36

[1]	Paweska JT. Rift valley fever[J]. Rev Sci Tech,2015,34(2):375-389.
[2]	Bird BH, McElroy AK. Rift valley fever virus: unanswered questions[J]. Antivir Res,2016,132(7):274-280.
[3]	Al Azraqi TA, El Mekki AA, Mahfouz AA. Rift Valley fever among children and adolescents in southwestern Saudi Arabia[J]. J Infect Public,2013,6(3):230-235.
[4]	Mansfield KL, Banyard AC, McElhinney L, et al. Rift Valley fever virus: A review of diagnosis and vaccination, and implications for emergence in Europe[J]. Vaccine,2015,33(42):5520-5531.
[5]	Baba M, Masiga DK, Sang R, et al. Has rift valley fever virus evolved with increasing severity in human populations in East Africa?[J]. Emerg Microbes Infec,2016,5(6):e58.
[6]	中华人民共和国国家卫生和计划生育委员会.我国发现一例输入性裂谷热病例[EB/OL]2016-8-12. URL
[7]	Lorenzo G, López-Gil E, Warimwe GM, et al. Understanding rift valley fever: contributions of animal models to disease characterization and control[J]. Mol Immunol,2015,66(1):78-88.
[8]	Muga GO, Onyango-Ouma W, Sang R, et al. Sociocultural and economic dimensions of Rift Valley fever[J]. Am J Trop Med Hyg, 2015,92(4):730-738.
[9]	Métras R, Cavalerie L, Dommergues L, et al. The Epidemiology of rift valley fever in mayotte: insights and perspectives from 11 years of data[J]. PLoS Negl Trop Dis,2016,10(6):e0004783.
[10]	Bosworth A, Ghabbari T, Dowall S, et al. Serologic evidence of exposure to rift valley fever virus detected in Tunisia[J]. N Micro N Infec,2016,9:1-7.
[11]	Owange NO, Ogara WO, Affognon H, et al. Occurrence of rift valley fever in cattle in Ijara district, Kenya[J]. Preve Veteri Med,2014,117(1):121-128.
[12]	Metras R, Jewell C, Porphyre T, et al. Risk factors associated with rift valley fever epidemics in South Africa in 2008-11[J]. Sci Rep,2015,5:9492.
[13]	Sindato C, Karimuribo ED, Pfeiffer DU, et al. Spatial and temporal pattern of rift valley fever outbreaks in Tanzania; 1930 to 2007[J]. PLoS One,2014,9(2):e88897.
[14]	Sow A, Faye O, Ba Y, Ba H, et al. Rift valley fever outbreak, southern Mauritania, 2012[J]. Emerg Infect Dis,2014,20(2):296-299.
[15]	Pepin M, Bouloy M, Bird BH, et al. Rift valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention[J]. Vet Res,2010,41(6):61.
[16]	Haneche F, Leparc-Goffart I, Simon F, et al. Rift valley fever in kidney transplant recipient returning from Mali with viral RNA detected in semen up to four months from symptom onset, France, autumn 2015[J]. Euro Comm Dis Bul,2016,21(18):1-4.
[17]	Wiley CA, Bhardwaj N, Ross TM, et al. Emerging infections of CNS: avian influenza A virus, rift valley fever virus and human parechovirus[J]. Brain Pathol,2015,25(5):634-650.
[18]	Ikegami T, Makino S. The pathogenesis of rift valley fever[J]. Viruses,2011,3(5):493-519.
[19]	Baer A, Shafagati N, Benedict A, et al. Protein phosphatase-1 regulates rift valley fever virus replication[J]. Antivir Res,2016,127:79-89.
[20]	Moy Ryan H, Gold B, Molleston Jerome M, et al. Antiviral autophagy restricts rift valley fever virus infection and is conserved from flies to mammals[J]. Immunity,2014,40(1):51-65.
[21]	Vuren PJV, Shalekoff S, Grobbelaar AA, et al. Serum levels of inflammatory cytokines in Rift Valley fever patients are indicative of severe disease[J]. J Virol,2015,12(1):159.
[22]	Hise AG, Traylor Z, Hall NB, et al. Association of symptoms and severity of rift valley fever with genetic polymorphisms in human innate immune pathways[J]. PLoS Negl Trop Dis,2015,9(3):e0003584.
[23]	Reed C, Steele KE, Honko A, et al. Ultrastructural study of rift valley fever virus in the mouse model[J]. Virology,2012,431(1-2):58-70.
[24]	Ross TM, Bhardwaj N, Bissel SJ, et al. Animal models of rift valley fever virus infection[J]. Virus Res,2012,163(2):417-423.
[25]	Terasaki K, Makino S. Interplay between the virus and host in rift valley fever pathogenesis[J]. J Innate Immun,2015,7(5):450-458.
[26]	Oreshkova N, Wichgers Schreur PJ, Spel L, et al. Nonspreading rift valley fever virus infection of human dendritic cells results in downregulation of CD83 and full maturation of bystander cells[J]. PLoS One,2015,10(11):e0142670.
[27]	Baudin M, Jumaa AM, Jomma HJ, et al. Association of rift valley fever virus infection with miscarriage in Sudanese women: a cross-sectional study[J]. Lancet Glob Health,2016,4(11):e864-e871.
[28]	Mcelroy AK, Nichol ST. Rift valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection[J]. Virology,2012,422(1):6-12.
[29]	Boshra H, Lorenzo G, Busquets N, et al. Rift valley fever: recent insights into pathogenesis and prevention[J]. J Virol,2011,85(13):6098- 6105.
[30]	De SMA, Nyakarahuka L, Purpura L, et al. Notes from the Field: Rift valley fever response--Kabale District, Uganda, March 2016[J]. Mmwr Morb Mortal Wkly Rep,2016,65(43):1200-1201.
[31]	Boushab MB, Savadogo M, Sow MS, et al. Severe hemorrhagic form of Rift Valley Fever in Mauritania[J]. Bull Soc Pathol Exot,2015,108(2):102-106.
[32]	Kahlon SS, Peters CJ, Leduc J, et al. Severe rift valley fever may present with a characteristic clinical syndrome[J]. Am J Trop Med Hyg,2010,82(3):371-375.
[33]	EI Imam M, EI Sabiq M, Omran M, et al. Acute renal failure associated with the rift valley fever: a single center study[J]. Saudi J Kidn Dis & Trans,2009,20(6):1047-1052.
[34]	Adam AA, Karsany MS, Adam I. Manifestations of severe rift valley fever in Sudan[J]. Int J Infect Dis,2010,14(2):e179-e180.
[35]	田丽丽，吴钶，孙玉兰,等.中国首例输入性裂谷热病例的流行病学调查[J].国际病毒学杂志,2016,23(6):361-363.
[36]	刘建礼，田茵，王飞,等.我国首例输入性裂谷热病毒感染病例的实验室检测[J].中国国境卫生检疫杂志,2016,39(4):233-236.

指标	7月21日	7月22日	7月23日	7月26日	8月19日	8月29日
WBC （× 10⁹/L）	6.77	5.91	2.47	9.09	8.52	7.81
NE（%）	71.50	66.00	80.00	68.00	61.8	57.60
血色素（g/L）	155.40	137.00	143.00	129.00	94.00	89.00
血小板（× 10⁹/L）	99.00	104.00	81.00	85.00	335.00	261.00
ALT （U/L）	5 910.00	5 360.00	1 968.00	857.00	194.00	42.00
AST（U/L）	7 570.00	686.00	612.00	124.00	90.00	29.60
TBil（μmol/L）	83.80	96.00	59.00	46.00	16.00	10.00
DBil（μmol/L）	71.80	85.00	52.00	37.00	11.00	5.00
白蛋白（g/L）	36.80	31.60	30.90	28.90	49.00	43.00
尿素氮（mmol/L）	35.19	37.00	19.00	18.00	8.00	5.03
肌酐（μmol/L）	1 005.70	097.00	540.00	397.00	139.00	86.00
肌酸激酶同工酶（ng/ml）	86.00	70.00	26.00	25.00	20.00	15.00
C-反应蛋白（mg/L）	18.50	16.30	7.20	8.20	5.00	0.50
降钙素原（ng/ml）	71.78	50.50	34.00	1.00	0.22	< 0.05
血脂肪酶（U/L）	58.10	122.00	468.00	192.00	30.00	20.00
血淀粉酶（U/L）	132.00	65.90	284.00	67.00	50.00	45.00

指标	7月21日	7月22日	7月23日	7月26日	8月19日	8月29日
WBC （× 10⁹/L）	6.77	5.91	2.47	9.09	8.52	7.81
NE（%）	71.50	66.00	80.00	68.00	61.8	57.60
血色素（g/L）	155.40	137.00	143.00	129.00	94.00	89.00
血小板（× 10⁹/L）	99.00	104.00	81.00	85.00	335.00	261.00
ALT （U/L）	5 910.00	5 360.00	1 968.00	857.00	194.00	42.00
AST（U/L）	7 570.00	686.00	612.00	124.00	90.00	29.60
TBil（μmol/L）	83.80	96.00	59.00	46.00	16.00	10.00
DBil（μmol/L）	71.80	85.00	52.00	37.00	11.00	5.00
白蛋白（g/L）	36.80	31.60	30.90	28.90	49.00	43.00
尿素氮（mmol/L）	35.19	37.00	19.00	18.00	8.00	5.03
肌酐（μmol/L）	1 005.70	097.00	540.00	397.00	139.00	86.00
肌酸激酶同工酶（ng/ml）	86.00	70.00	26.00	25.00	20.00	15.00
C-反应蛋白（mg/L）	18.50	16.30	7.20	8.20	5.00	0.50
降钙素原（ng/ml）	71.78	50.50	34.00	1.00	0.22	< 0.05
血脂肪酶（U/L）	58.10	122.00	468.00	192.00	30.00	20.00
血淀粉酶（U/L）	132.00	65.90	284.00	67.00	50.00	45.00

Please choose a citation manager

Content to export